2018 Annual Meeting

Pre-Conference


CIS, along with AMLI, will once again be offering the Update on Diagnostic Advances in Primary Immunodeficiencies on Thursday, April 26, prior to the start of the 2018 Annual Meeting. This pre-conference will provide an intellectual forum for attendees to discuss the latest in diagnostic advances in the field if immune regulation and dysregulation.
 

View Program


 

Annual Meeting Program

The Annual Meeting and Update in PID pre-conference will provide a venue for the presentation of the newest immune deficiency diseases and the pathogenesis of these defects in molecular terms. The substance of the conference will be cutting edge clinical and basic science research. The draft program is available below.

 

Along with the Annual Meeting, there are a number of additional networking and educational opportunities available to attendees. Click below to learn more about these additional sessions.

 

All plenary sessions will take place in Grand West and Centre at the Sheraton Centre. All exhibits and poster sessions will be in the Sheraton Hall/Osgoode Ballroom.
 

Networking & Additional Education Sessions

Open AllClose All
  Thursday, April 26

7:00 am – 2:00pm
Update on Diagnostic Advances in Primary Immunodeficiencies Pre-Conference
(Separate Registration Required)
 

2:30pm – 2:40pm
Welcome from CIS President

Roshini Abraham, PhD

Mayo Clinic

 

2:40pm - 4:00pm
CIS Fellowship Grantee Presentations

1.5 AMA PRA Category 1 Credits™

 

Moderators:
Roshini Abraham, PhD
Mayo Clinic

Shanmuganathan Chandrakasan, MD
Emory University School of Medicine
Children's Healthcare of Atlanta

 

Speaker:
Site-Specific Gene Therapy In The Treatment Of X-Linked Hyper-IgM Syndrome
Caroline Kuo, MD
University of California, Los Angeles


Oral Abstracts:
Conditioning with anti-CD45 immunotoxin in a mouse model of hypomorphic Rag1 deficiency allows complete reconstitution of the immune system with lack of toxicity            
Enrica Calzoni, MD
Laboratory of Clinical Immunology and Microbiology, DIR, NIAID, NIH, DHHS


PTCRA mutations yield novel T cell immune deficiency 
Sarah Henrickson, MD, PhD
The Children's Hospital of Philadelphia

 

4:00pm - 6:00pm
Plenary Session: Patient Management: Controversies in PIDs

2 AMA PRA Category 1 Credits™


Moderators:
Steve Holland, MD, National Institute of Allergy and Infectious Disease, NIH
Troy Torgerson, MD, PhD, University of Washington & Seattle Children's Research Institute

Panelists:
Jack Routes, MD
Medical College of Wisconsin

Alexandra Freeman, MD
National Institute of Health

Donald Vinh, MD
McGill University Health Centre

Klaus Warnatz, MD
Medical Center, University of Freiburg

Elie Haddad, MD, PhD
CHU Ste-Justine, University of Montreal

Lisa Forbes, MD
Baylor College of Medicine

Catharina Schuetz, MD
Ulm University Medical Center, Pediatrics, Germany

 

6:00pm - 7:00pm
Robert A. Good Lecture

1 AMA PRA Category 1 Credits™


Moderator:

Troy Torgerson, MD, PhD
University of Washington & Seattle Children's Research Institute


Speaker:
Genetic Immunodeficiencies and Bone Marrow Failure
Akiko Shimamura, MD, PhD
Dana Farber/Boston Children's Cancer and Blood Disorders Center

  Friday, April 27

7:00 am - 8:00 am: Breakfast

7:00 am - 8:00 am
Genomics 101 A
*SESSION FULL*
Elgin--Second Floor

  • Isabelle Meyts, MD, Leuven University, Belgium
  • Asbjorg Stray-Pedersen, MD, PhD, Oslo University Hospital, Norway
     

7:00 am - 8:00 am
Genomics 101 B
*SESSION FULL*

Peel--Mezzanine Level

  • Ivan Chinn, MD, Baylor College of Medicine
  • Janet Chou, MD, Children’s Hospitalof Boston

 

8:00am - 9:30am
Plenary Session: Cross-Talk: PIDs from the Perspective of Other Specialties

1.5 AMA PRA Category 1 Credits™


Moderators:

Elena Hsieh, MD, University of Colorado


Speakers:
TBD
Aleixo Muise, MD, PhD
Sick Kids Toronto

When It Rains, It Pours - Tumor Predisposition in PID and Vice Versa
Markus Seidel, MD
Medical University Graz

TBD
Susanne Benseler, MD
Alberta Children’s Hospital, Calgary

TBD
Markus Boos, MD, PhD
Seattle Children’s Hospital

 

Oral Abstract:
Clinical, imaging, and pathology features of cytotoxic T-lymphocyte antigen 4 haploinsufficiency associated neuroinflammation   
Matthew Schindler, MD
National Institute of Neurological Disorders and Stroke


9:30am - 9:45am: Morning Break

9:45am - 11:30am
Plenary Session: The Thymus: Understanding the Biology, Diseases, and Treatment

2 AMA PRA Category 1 Credits™

 

Moderators:

Stuart Turvey, MBBS, DPhil, FRCPC, University of British Columbia

Joyce Yu, MD, Morgan Stanley Children's Hospital/Columbia University Medical Center

 

Speakers:
Fixing To Regenerate Human T-Lymphopoiesis
Juan Carlos Zúñiga-Pflücker, PhD
Sunnybrook Research Institute, Canada

Mechanisms That Regulate Pathways in Intrathymic T-cell Development
Graham Anderson, PhD
University of Birmingham, UK

Thymus Transplant and Update on Thymus Transplant Task Force
Mary Louise Markert, MD, PhD
Duke University School of Medicine

Oral Abstract:
RAG1 HYPOMORPHIC MOUSE MUTANTS SHOW PARTIAL PRESERVATION OF THYMOCYTE DEVELOPMENT BUT PECULIAR ABNORMALITIES OF THYMIC EPITHELIAL CELL PHENOTYPE
Marita Bosticardo, PhD
NIAID, NIH

 

11:30am - 1:00pm
Lunch/Exhibit Hall/Poster Hall Open

Sheraton Hall/Osgoode Ballroom

 

11:30am - 12:30pm
WCIS Luncheon

Grand East

12:00 pm - 12:20 pm     
Lightning Poster Presentations

Osgoode Ballroom

12:20 pm - 1:00 pm     
Poster Viewing

Sheraton Hall/Osgoode Ballroom

1:00 pm - 1:30 pm     
CIS Business Meeting


1:30pm - 3:00pm
Plenary Session: Immune Complications Caused by Therapeutic Intervention

1.5 AMA PRA Category 1 Credits™


Moderators:

James Chipeta, BSc., MBChB, PhD, University of Zambia

Monica Lawrence, MD, University of Virginia
 

Speakers:
Immune Dysregulation Following the Use of Checkpoint Inhibitors for Malignancies
Maria Suarez-Almazor, MD, PhD
MD Anderson Cancer Center

Immune Defects and Complications Following CAR-T Cell Therapies
Kevin Curran, MD
Memorial Sloan Kettering Cancer Center

Fontan and T Cell Lymphopenia
Jen Heimall, MD
Children's Hospital of Philadelphia
 

Oral Abstract:
VEDOLIZUMAB FOR AUTOIMMUNE ENTEROPATHY IN PRIMARY IMMUNODEFICIENCY: A CASE SERIES OF OUTCOMES   
Travis Sifers, MD
Icahn School of Medicine at Mount Sinai



3:00pm - 3:15pm: Afternoon Break

3:15pm - 4:15pm
Plenary Session: Registries

1 AMA PRA Category 1 Credits™
*Sponsored by USIDNET*


Moderators:
Kathleen Sullivan, MD, PhD
Children's Hospital of Philadelphia
Charlotte Cunningham-Rundles, MD, PHD
Mt. Sinai Medical Center

 

Speaker:
TBD
Nizar Mahlaoui, MD, MSc, MPH
French National Reference Center for Primary Immune Deficiencies (CEREDIH), Necker Enfants Malades Hospital, University Paris Descartes, France

 

Oral Abstracts:

PROPHYLACTIC ANTIBIOTICS VS. IMMUNOGLOBULIN REPLACEMENT IN PATIENTS WITH SPECIFIC ANTIBODY DEFICIENCY
Joud Hajjar, MD
Baylor College of Medicine   

 

IMPACT OF PULMONARY COMPLICATIONS ON QUALITY OF LIFE IN THE USIDNET REGISTRY    
Joyce Yu, MD
Columbia University Medical Center

 

NEUROLOGIC COMPLICATIONS OF COMMON VARIABLE IMMUNODEFICIENCY: FINDINGS FROM THE USIDNET REGISTRY
Jenna Nguyen, MD
University of California-San Francisco


4:15pm - 4:30pm: Break

4:30pm - 5:30pm
Plenary Session:
CIS Rose/Fahey Founders Lecture

1 AMA PRA Category 1 Credits™

Moderator:

Megan Cooper, MD, PhD, Washington University in St. Louis


Speaker:
Tracking the Anti-Donor Alloresponse in Transplant Patients
Megan Sykes, MD
Columbia Center for Translational Immunology


5:30pm - 6:00pm
Plenary Session:
PID Year in Review

Article: "X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability" Journal of Allergy and Clinical Immunology, Volume 141, Issue 1, 365 - 371
Presenter: Kelli Williams, MD, MPH, Medical University of South Carolina
Mentor: Alexandra Freeman, MD, NIH

 

Article: "BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency." Nat Immunol. 2017 Jul;18(7):813-823. doi: 10.1038/ni.3753.
Presenter: Hey Chong, MD, PhD, University of Pittsburgh Children's Hospital
Mentor: Isabelle Meyts, MD, PhD, University Hospitals Leuven

 

Article: "Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib." Blood Nov 2017, 130 (21) 2307-2316; DOI: 10.1182/blood-2017-08-801191
Presenter: Nicholas Hartog, MD, Helen DeVos Children's Hospital and Spectrum Health Medical Group
Mentor: Nicola Wright, MD, Alberta Children's Hospital

 

Article: "Long-term follow up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study." J Allergy Clin Immunol. 2017 Dec 11. pii: S0091-6749(17)31893-6. doi: 10.1016/j.jaci.2017.10.041
Presenter: Kiran Patel, MD, Emory University
Mentor: Magda Carneiro-Sampaio, MD, PhD, Universidade De Sao Paulo

 

Article: “Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase." J Allergy Clin Immunol 140(4): 1054-1067 e1010
Presenter: Joud Hajjar, MD, Baylor College of Medicine
Mentor: Thomas Isskeutz, MD, Dalhousie University

  Saturday, April 28

7:00 am - 8:00 am: Breakfast

7:00 am - 8:00 am
Flow 101 A
*SESSION FULL*
Elgin--Second Floor

  • Troy Torgerson, MD, PhD, University of Washington
  • David Hagin, MD, Tel-Aviv Sourasky Medical Center, Israel


7:00 am - 8:00 am
Flow 101 B *SESSION FULL*
Peel--Mezzanine Level

  • Michael Keeney, London Health Sciences Center (Ontario)
  • James Verbsky, MD, PhD, Medical College of Wisconsin


8:00 am - 9:50 am    
Plenary Session: Novel Insights and Approaches to Regulating Immunity

2 AMA PRA Category 1 Credits™


Moderators:

Sarah Henrickson, MD, PhD, Children's Hospital of Philadelphia

Manish Butte, MD, PhD, UCLA

Speakers:
New Treatments for Interferonopathies
Yanick Crow, BMedSci, MBBS, MRCP, PhD
University of Manchester, UK

Tregs Isolated From Thymus as a Potential Cell Therapy
Megan Levings, PhD
BC Children's Hospital Research Institute, Canada

New Insights in Treg Biology That Impact Human Disease
Ciriaco A. Piccirillo, MD
McGill University, Canada

Eculizumab for Early-Onset IBD in CD55 Deficiency
Kaan Boztug, MD
University of Vienna

Ustekinumab in Treating Complications of LAD
Steve Holland, MD
National Institute of Allergy and Infectious Disease, NIH

 

Oral Abstract:
FOXP3 GENE TRANSFER IN T CELLS AND FOXP3 GENE EDITING IN HSC AS NOVEL TREATMENT OPTIONS FOR IPEX SYNDROME    
Rosa Bacchetta, MD
Stanford University School of Medicine



9:50 am - 10:00 am: Morning Break

10:00 am - 11:30 am     
Plenary Session: Transplantation: From Bone Marrow to Solid Organ

1.5 AMA PRA Category 1 Credits™

 

Moderators:

Hélène Decaluwe, MD, PhD, FRCPC, CHU Sainte-Justine and University of Montreal  

Eyal Grunebaum, MD, Hospital for Sick Children

 

Speakers:
PIDTC Year in Review

  • Elie Haddad, MD, PhD, CHU Ste-Justine, University of Montreal
  • Elizabeth Kang, MD, National Institute of Allergy and Infectious Disease, NIH
  • Morton Cowan, MD, UCSF Benioff Children's Hospital

 

SOT/HCT Combined Transplantation
Paul Szabolcs, MD
Children's Hospital of Pittsburgh

 

Oral Abstracts:
ABERRANT T CELL ACTIVATION AND EXHAUSTION DEVELOPS IN POORLY RECONSTITUTED SCID SURVIVORS AFTER TRANSPLANT AND CORRELATES WITH THE ABSENCE OF CONDITIONING REGIMEN: A PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM (PIDTC) STUDY

Hélène Decaluwe, MD, PhD, FRCPC
CHU Sainte-Justine and University of Montreal   

 

LATIN-AMERICAN CONSENSUS ON THE MANAGEMENT OF PATIENTS WITH SEVERE COMBINED IMMUNODEFICIENCY, PART 1: “SUPPORTIVE MEASURES DURING THE TIME FROM DIAGNOSIS TO DEFINITIVE TREATMENT.”    
Juan Carlos Bustamante Ogando, MD
National Institute of Pediatrics    


11:40 am -12:00 pm     
Plenary: Patient Advocacy Groups Update

.5 AMA PRA Category 1 Credits™

12:00 am - 2:00 pm     
Lunch/Exhibit Hall Open

Sheraton Hall/Osgoode Ballroom

1:00 pm - 1:20 pm     
Lightning Poster Presentations

Osgoode Ballroom

1:20 pm - 2:00 pm     
Poster Viewing

Sheraton Hall/Osgoode Ballroom

2:00 pm - 3:30 pm     
Plenary: Tales from the Listserv

1.5 AMA PRA Category 1 Credits™

 

Moderators:

  • Eric Allenspach, MD, PhD
    University of Washington & Seattle Children's Hospital
  • Elie Haddad, MD, PhD
    CHU Ste-Justine, University of Montreal
  • Mikko Seppänen, MD, PhD
    Helsinki University Central Hospital


3:30 pm - 4:00 pm: Afternoon Break

4:00 pm - 5:00 pm     

Plenary: Richard Schiff Lecture
1 AMA PRA Category 1 Credits™
*Sponsored by Shire*


Moderator:
Jack Routes, MD, Medical College of Wisconsin

 

Speaker:
Unraveling Graft-Versus-Host Disease Pathogenesis to Develop New Treatments
Bruce Blazar, MD
University of Minnesota


5:00 pm - 5:30pm     
Presidential Award Lecture
.5 AMA PRA Category 1 Credits™
 

Moderator:

Roshini Abraham, PhD, Mayo Clinic

 

Speaker:
Immune Dysregulation In T Cell Immunodeficiencies: Insights From The Analysis Of Repertoire Diversity And Composition
Luigi Notarangelo, MD
NIH


5:30 pm - 7:00 pm     
Closing Reception

Sheraton Hall/Osgoode Ballroom

  Sunday, April 29

7:00 am - 8:00 am: Breakfast

8:00 am - 10:30 am    
Plenary Session: Hot New Defects in Primary Immunodeficiencies

2.5 AMA PRA Category 1 Credits™

Moderators:

Andrew Cant, MD, Newcastle General Hospital

Lahari Rampur, MD, University of Washington Medical Center, Seattle

 

Speakers:
New Autoinflammatory Defects
Ivona Aksentijevich, MD
National Institutes of Health

TBD
Helka Goos, MD
University of Helsinki

TLR7 Deficiency
Eric Meffre, PhD
Yale University

 

Oral Abstract:
HUMAN PI3KGAMMA DEFICIENCY WITH HUMORAL DEFECTS AND LYMPHOCYTIC INFILTRATION OF BARRIER TISSUES    
Carrie Lucas, PhD
Yale University

 

Abstracts

All notifications for submitted abstracts have been sent out. If you submitted an abstract, but have not seen your notification please check your spam/junk email. Questions can be directed to Sarah Tulley at stulley@clinimmsoc.org

 

Late-Breaking Abstracts:

NOTIFICATIONS WILL BE SENT BY MARCH 1ST OF ACCEPTED LATE-BREAKING ABSTRACTS

 

Additional Information

Accepted late-breaking abstracts will be slotted for oral presentation in any of the plenary sessions of the Annual Meeting. A maximum of 3 abstracts will be accepted for oral presentation. If an abstract is not selected for oral presentation there will be no other opportunity to present.

 

Topics of Interest

The following is a list of categories of interest to CIS for abstract submission. This is not an inclusive list and abstracts on categories not listed will also be accepted.

  •         B cell biology
  •         Biological mechanisms of PID
  •         Hematopoietic cell transplantation and gene therapy
  •         Immune dysregulation in PID
  •         Immune modulating therapies
  •         Immunoglobulin replacement therapy
  •         Infections in PIDs
  •         Innate immunity
  •         NK cell biology
  •         Novel genetic etiologies of PIDs
  •         Phenotypic and molecular spectrum of Primary Immune Deficiency
  •         PID registries
  •         T cell biology
  •         Other topics related to clinical immunology

Registration Fees


On-site registration will be available if you are unable to register online anytime before March 30, 2018.


ALL 101 SESSIONS ARE FULL. If you would like to be added to the waitlist please email Sarah Tulley at stulley@clinimmsoc.org.

Pre-Conference Advance Registration
(Feb. 9 - March 30)
Update on PID Only $300
Update on PID Discount with Annual Meeting $250
Annual Meeting Advance Registration
(Feb. 9 - March 30)
CIS Regular Member $550
CIS Trainee Member $250
CIS Associate / Allied Health Member $250
Non-Member $750
Non-Member: Trainee $300
Non-Member: Allied Health $400
Industry / Sponsor / Exhibitor $350
Developing Country (Member or Non-Member) $250
One Day Registration (Member or Non-Member) $300
101 Session $15

Register Now

Register for the 2018 CIS Annual Meeting to ensure your spot at the preeminent North American conference dedicated to immune deficiency and dysregulation. The 2018 Annual Meeting will feature the latest in clinical and basic science research. This is your chance to hear and learn from experts from around the globe speak on the latest in immune deficiency and dysregulation.

 

Get Started

Hotel Information

The CIS 2018 Annual Meeting will be held at Sheraton Centre Toronto in Toronto, Ontario, Canada.

Sheraton Centre Toronto
123 Queen Street West
Toronto, ON, M5H 2M9, Canada
Ph: 416.361.1000

Attendees of the CIS 2018 Annual Meeting can reserve a room under the CIS block for CAD $249/night ($199 USD) (single/double occupancy), excluding taxes.

The deadline for reservations at this discounted rate is March 23, 2018

About the Sheraton Centre Toronto
Located in the heart of Downtown Toronto, the Sheraton Centre is close to the city's top attractions, including the Hockey Hall of Fame, the CN Tower, Casa Loma and the Royal Ontario Museum, as well as providing attendees with access to world class shopping, dining and entertainment. We look forward to seeing you in Toronto!
 

Book Your Hotel

Canada Travel Information

ALL VISITORS

To visit Canada, all travelers will need to meet some basic requirements:

  • Have a valid travel document, like a passport
  • Be in good health
  • Have no criminal or immigration-related convictions
  • Be able to explain to an immigration officer that you have ties—such as a job, home, financial assets or family—that will take you back to your home country
  • Explain to an immigration officer that you will leave Canada at the end of your visit
  • Have enough money for your stay (The amount of money you will need depends on how long you will stay and if you will stay in a hotel, or with friends or relatives).

ENTERING FROM THE UNITED STATES
  • The Canada Border Services Agency (CBSA) recommends that all US citizens carry a valid passport. A passport may be required by your airline or transportation authority.
  • If you are a United States citizen, be sure to carry proof of citizenship, such as a passport, along with photo identification. If you are a permanent U.S. resident, carry proof of your status such as a U.S. Permanent Resident Card.

ENTERING FROM NON-US COUNTRIES
  • All non-US visitors to Canada will be required to obtain either an Electronic Travel Authorization (eTA) or a visa for the length of their stay. Click below to determine which travel document you will
     

Do You Need an eTA or a Visitor Visa?

Exhibitors and Sponsors

Dear Colleagues,

On behalf of the Clinical Immunology Society (CIS), we invite you to participate in the 2018 Annual Meeting: Immune Deficiency & Dysregulation North American Conference taking place April 26-29, 2018 at the Sheraton Centre Toronto in Toronto, Ontario, Canada.

CIS is the key inter-disciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology and to promote excellence in the care of patients with immunological and immune dysregulatory disorders.

Your participation is essential to the success of the Annual Meeting. Please take this opportunity to meet hundreds of healthcare professionals and educate them about your products and services. Join us for this momentous occasion that promises to be one of thebest conferences on primary immunodeficiency. We look forward to seeing you in Toronto!

Regards,

Roshini Abraham, PhD
Mayo Clinic
2018 Program Committee Co-Chair

Troy Torgerson, MD, PhD
University of Washington
2018 Program Committee Co-Chair

Oral Presentation Information

All speakers can access the speaker login site here. If you need your login credentials resent to you, please contact Sarah Tulley, CIS Meetings Manager, stulley@clinimmsoc.org.
 

Important Dates

February 9, 2018

Early Bird Registration Closes

 

March 23, 2018

Housing Closes

 

March 30, 2018

Online Registration Closes
*On-site registration will be available*

top